Peptide record

TPDB11702

Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
37 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11702
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 DRAMP Peptipedia
standard
No
A 37-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, DRAMP, and Peptipedia, with an available 3D structural model.
Sequence
GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY
Physicochemical Analysis
C202H356N64O47
CHMSWV
K
4433.45
11.96
14
2
12
+12
12.33
-1.097
97.57
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
1490
33.61
5
Residue Composition
number
1
A
5
R
1
N
1
D
0
C
1
E
2
Q
3
G
0
H
3
I
6
L
9
K
0
M
1
F
2
P
0
S
1
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 1 R: 5 N: 1 D: 1 C: 0 E: 1 Q: 2 G: 3 H: 0 I: 3 L: 6 K: 9 M: 0 F: 1 P: 2 S: 0 T: 1 W: 0 Y: 1 V: 0
Chemical Descriptors
37
C202H356N64O47
4433.45
11.96
+12
12.33
-1.097
Evidence Records 3 records
Evidence 1 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Bactericidal activity of mammalian cathelicidin-derived peptides. | Infect Immun | 2000
Evidence 2 Activity

Activity

1% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
1% Hemolysis | 64 | µg/mL | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Evidence 3 Activity

Activity

% Hemolysis
Toxicity
1 %
Hemolytic
Hemolytic_activity: [Ref.10768969]non-hemolysis against Human erythrocytes up to 500 µg/ml.##[Ref.26656394]1% hemolysis against Horse erythrocytes at 64 µg/ml.

Target

erythrocytes

Source & Reference

NA
DRAMP
Antimicrob Agents Chemother. 2001 Oct 45(10):2838-2844.##Infect Immun. 2000 May 68(5):2748-2755.##PLoS One. 2015 Dec 11 10(12):e0144611.##Front Microbiol. 2018 Sep 7 9:2153.##PLoS One. 2018 May 31 13(5):e0197742.